BB Biotech backs Actelion board
This article was originally published in Scrip
Executive Summary
BB Biotech, the CHF 1.2 billion Swiss life sciences fund, has thrown its weight behind the existing Actelion management team at the upcoming general meeting of shareholders. Describing itself as a critical shareholder demanding good corporate stewardship, the BB Biotech board has declared its intention to support the proposals being put forward by Actelion at the 5 May meeting.